Lucid Diagnostics
NASDAQ: LUCDLake Forest, US · Delaware corporation · 1 known investors
Find your way into Lucid Diagnostics
154 people in our graph share verified history with the Lucid Diagnostics team — schools, employers, funds. One of them is your warm intro.
George Bellunlockedknows Shaun O'Neil · together at Harris Interactive Inc. (overlapped)
×10knows the team · via Rochester Institute of Technology
knows the team · via AngioDynamics
Lucid Diagnostics develops tests for the early detection of esophageal precancer using targeted next-generation sequencing, aimed at helping clinicians detect and treat the condition before it progresses to cancer. The company operates a CLIA-certified, CAP-accredited clinical lab licensed by the New York State Department of Health.
Founders & leadership
MA
Michael A GordoninGeneral Counsel
SO
Shaun O'NeilinPresident and Chief Operating OfficerShaun O'Neil is an executive officer at Lucid Diagnostics, a clinical diagnostics company that develops tests for early detection of esophageal precancer using next-generation sequencing.
LA
Lishan AkloginChairman & CEO
DM
Dennis McGrathinExecutive
BD
Brian deGuzmaninChief Technology Officer & Chief Compliance Officer
DM
Dennis M. McGrathinChief Financial Officer
SM
Shaun M. O'NeilinPresident and Chief Operating OfficerShaun M. O'Neil is President and Chief Operating Officer of Lucid Diagnostics, a clinical diagnostics company that develops DNA-based tests for early detection of esophageal precancer in patients with chronic acid reflux.
VT
Victoria T. LeeChief Medical Officer
Board
DA
DENNIS A. MATHEISBoard director
RM
Ronald M SparksBoard director
DJ
Debra J. WhiteBoard director
SN
Investors · 1
Reported raises · per SEC filings
Form D private placements$51.7M disclosed across 4 rounds · 2023–2024
▶$21.9MraisedDec 2024 · 7 investors · BiotechnologyRule 506(b)
▶$21.9MraisedDec 2024 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- MICHAEL A. GORDONExecutive Officer
- DENNIS A. MATHEISDirector
- SHAUN O'NEILExecutive Officer
- RONALD M. SPARKSDirector
- LISHAN AKLOGExecutive Officer, Director
- DEBRA J. WHITEDirector
- STANLEY N. LAPIDUSDirector
- DENNIS M. MCGRATHExecutive Officer
- JAMES L. COXDirector
- JACQUE J. SOKOLOVDirector
- Offering amount
- $21.9M
- Amount sold
- $21.9M
- First sale
- Nov 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5MraisedNov 2023 · 2 investors · BiotechnologyRule 506(b)
▶$5MraisedNov 2023 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Stanley LapidusDirector
- Michael A GordonExecutive Officer
- Jacque J SokolovDirector
- Dennis McGrathExecutive Officer
- Shaun O'NeilExecutive Officer
- James L CoxDirector
- Ronald M SparksDirector
- Debra WhiteDirector
- Lishan AklogExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $5M
- Minimum investment
- $250K
- First sale
- Oct 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$11.1MraisedApr 2023 · 1 investors · BiotechnologyRule 506(b)
▶$11.1MraisedApr 2023 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Debra WhiteDirector
- James L CoxDirector
- Shaun O'NeilExecutive Officer
- Michael A GordonExecutive Officer
- Ronald M SparksDirector
- Dennis McGrathExecutive Officer
- Jacque J SokolovDirector
- Lishan AklogExecutive Officer, Director
- Stanley LapidusDirector
- Offering amount
- $11.1M
- Amount sold
- $11.1M
- First sale
- Mar 2023
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$13.6MraisedMar 2023 · 4 investors · BiotechnologyRule 506(b)
▶$13.6MraisedMar 2023 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Shaun O'NeilExecutive Officer
- Ronald M SparksDirector
- Debra WhiteDirector
- Dennis McGrathExecutive Officer
- Lishan AklogExecutive Officer, Director
- Jacque J SokolovDirector
- Stanley LapidusDirector
- Michael A GordonExecutive Officer
- James L CoxDirector
- Offering amount
- $20M
- Amount sold
- $13.6M
- Minimum investment
- $250K
- First sale
- Mar 2023
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 6
by search overlap
Seeking Alpha29 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Quest Diagnostics25 shared keywordsQuest Diagnostics is the world's leading provider of diagnostic information services, serving one in three adult Americans and half of US physicians and hospitals. The company offers diagnostic insights and testing services to consumers and healthcare providers to support health decision-making.
Simply Wall St25 shared keywordsSimply Wall St is an investment platform that provides financial data visualization and analysis tools for individual investors. The platform serves long-term investors globally by simplifying complex market information into visual and narrative formats to make stock investing more accessible.
Robinhood25 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Lucid Software, Inc.24 shared keywordsLucid provides cloud-based visual collaboration and communication software for teams to visualize workflows, create diagrams, whiteboards, and roadmaps. The platform serves enterprise customers across Fortune 500 companies and is used by over 100 million individual users globally.
Foresight Diagnostics23 shared keywordsForesight Diagnostics develops ultra-sensitive molecular diagnostic tests that combine genomics and bioinformatics to detect minimal residual disease and circulating tumor DNA across multiple cancer types. Its offerings support oncology drug development, clinical trials, and patient care for academic and biopharma partners.
Companies competing with Lucid Diagnostics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Lucid Diagnostics do?
- Lucid Diagnostics develops tests for the early detection of esophageal precancer using targeted next-generation sequencing, aimed at helping clinicians detect and treat the condition before it progresses to cancer. The company operates a CLIA-certified, CAP-accredited clinical lab licensed by the New York State Department of Health.
- Who are Lucid Diagnostics's investors?
- Lucid Diagnostics's investors include CWRU Technology Ventures.
- How much funding has Lucid Diagnostics raised?
- Lucid Diagnostics has disclosed $51.7M raised across 4 rounds.
- Where is Lucid Diagnostics headquartered?
- Lucid Diagnostics is headquartered in Lake Forest, US.